Drug Trial Radar · NCT07936084
Clinical Trial of GenSci136 in Patients With Myasthenia Gravis
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase Ib/II Clinical Trial of GenSci136 in Patients with Myasthenia Gravis
Conditions
- Patients With MG (gMG and oMG)
Interventions
GenSci136 for injectionDrug
GenSci136 for injection, administered the medication according to the requirements of the protocal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes from baseline in the incidence and severity of TEAEs/SAEs occurring within 10 weeks after the first dose and other safety measures (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG], etc.).Time frame: From time of informed consent to 10 weeks after the first dose of GenSci136
- Changes from baseline in the incidence and severity of TEAEs/SAEs occurring within 10 weeks after the first dose and other safety measures (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG], etc.).Time frame: Approximately 26 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital ,Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.